Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: Results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 5, 2007, Pages 415-423

  Seeholzer, Niels ^a,b,d   Thürlimann, Beat ^c   Köberle, Dieter ^c   Hess, Dagmar ^c   Korte, Wolfgang ^a,c  

^a Institute for Clinical Chemistry and Hematology   (Switzerland)

^b Spital   (Switzerland)

^c Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^d NONE   (Switzerland)

Author keywords

Breast cancer; Chemotherapy; Hemostatic activation; Low molecular weight heparin; Transforming growth factor beta 1

Indexed keywords

CLEMASTINE; DOCETAXEL; ENOXAPARIN; FIBRIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RANITIDINE; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD CLOTTING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSESTHESIA; DYSGEUSIA; EPIPHORA; FEMALE; GENERALIZED EDEMA; GRANULOCYTOPENIA; HOT FLUSH; HUMAN; INTRADUCTAL CARCINOMA; NAIL; NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ENOXAPARIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HUMANS; MIDDLE AGED; TAXOIDS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34250839955     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3281139c1d     Document Type: Article

References (52)

1. Parker S, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA-A Cancer J Clin 1997; 47:5-27.
2. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006; 5:1779-1787.
3. Denekamp J. Inadequate vasculature in solid tumours: consequences for cancer research strategies. Br J Radiol 1992; 24:111-117.
4. Norrby K. 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis. Int J Exp Pathol 2000; 81:191-198.
5. Zucker S, Mirza H, Conner CE, Lonrenze Af, Drews MH, Bahou W, et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase activation and cell proliferation. Int J Cancer 1998; 75:780-786.
6. Boccacio C, Medico E. Cancer and blood coagulation. Cell Mol Life Sci 2006; 63:1024-1027.
7. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Hemost 1998; 80:10-23.
8. Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemos 2002; 28:45-52.
9. Murray JC. Coagulation and cancer. Br J Cancer 1991; 64:422-424.
10. McCulloch P, George WK. Warfarin inhibiton of metastasis: the role of anticoagulation. Br J Surg 1987; 74:879-883.
11. Inufusa H, Nakatani Y, Adachi T, Wakano T, Nakajima A, Nakamura M, et al. Correlation of prognosis of breast cancer patients and expression of Ley with acts as a cofactor of tumor procoagulant. Int J Oncol 1998; 13:481-487.
12. Vrana JA, Stang MT, Grande JP, Getz MJ. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res 1996; 56:5063-5070.
13. Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localisation in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152:399-411.
14. Von Tempelhoff GF, Dietrich M, Hommel G, Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable beast cancer. J Clin Oncol 1996; 14:2560-2568.
15. Rella C, Coviello M, Giotta F, Maiello E, Colavito P, Colangelo D, et al. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 1996; 40:151-159.
16. Flossel C, Luther T, Albrecht S, Kotzsch M, Muller M. Constitutive tissue factor expression of human breast cancer cell line MCF-7 is modulated by growth factors. Eur J Cancer 1992; 28:1999-2002.
17. Ozyilkan O, Baltali E, Ozdemir O, Tekzuman G, Kirazli S, Firat D. Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin compex and thrombin-antithrombin II complex in female breast cancer. Tumori 1998; 84:364-367.
18. Gunji Y, Lewis J, Gorelik E. Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells. Blood Coagul Fibrinol 1990; 1:663-672.
19. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliot CG, et al. Subcutaneous LMWH compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326:975-982.
20. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Catelan AM, et al. Comparison of subcutaneous LMWH with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339:441-445.
21. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with LMWH versus standard heparin [letter]. Lancet 1992; 339:1476.
22. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22:1944-1948.
23. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2:1266-1271.
24. Klerk CK, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23:2130-2135.
25. Olander JV, Bremer ME, Marasa JC, Feder J. Fibrin-enhanced endothelial cell organization. J Cell Physiol 1985; 125:1-9.
26. Vlodavsky L, Miao HQ, Benezra M, Lider O, Bar-Shavit R, Schmidt A, et al. Involvement of the extracellular matrix, heparin sulphate proteoglycans, and heparin sulphate degrading enzymes in angiogenesis and metastases. In: Bickel R, Lewis CE, Ferrara N, editors. Tumor angiogenesis. New York, NY: Oxford University Press; 1997. pp. 125-140.
27. Lebeau B, Chastang C, Bréchot JM, Capron F, Dautzenberg B, Delaisements C, et al. Subcutaneous heparin increases survival in small cell lung cancer. 'Petites cellules' Group. Cancer 1994; 74:38-45.
28. Robert F, Busby E, Marques MB, Reynolds RE, Carey DE. Phase II study of docetxel plus enoxaparin in chemotherapy-naïve patients with metastatic non-small cell lung cancer: preliminary results. Lung Cancer 2003; 42:237-245.
29. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-beta1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995; 222:155-162.
30. Kalemkerian GP. Growth factors. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, editors. Lung cancer, principles and practice. Philadelphia, PA: Lippincott Williams and Wilkins; 2000. p. 188.
31. Jetten AM, Vollberg TM, Nervi C, George MD. Positive and negative regulation of proliferation and differentiation in tracheobronchial epithelial cells. Am Rev Respir Dis 1990; 142:36-39.
32. 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999; 17:607-614.
33. 1 in patients with hepatocellular carcinoma. Cancer 1994; 73:2275-2279.
34. 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996; 110:375-382.
35. Derynck R, Akhurst RJ, Balmain A. TGF-beta signalling in tumor suppression and cancer progression. Nat Genet 2001; 29:117-129.
36. 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52:4261-4264.
37. 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 1993; 53:3849-3852.
38. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for TGF-beta1 associates with disease progression in human breast cancer. Cancer Res 1992; 52:6949-6952.
39. Oda K, Hori S, Itoh H, Osamura RY, Tokuda Y, Kubota M, et al. Immunohistochemical study of TGF-beta, fibronectin, and fibronectin receptor in invasive mammary carcinomas. Acta Path Jpn 1992; 42:6445-6450.
40. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, Ivanisevic-Milovanovic O, et al. Elevated plasma levels of TGF-beta1 in patients with advanced breast cancer: association with disease progression. Eur J Cancer 2003; 39:454-461.
41. Hainswoth JD, Burris HA 3rd, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administred by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16:2164-2168.
42. Miller AB, Hoogstraten B, Staquest M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
43. Maisano R, Mare M, Caristi N, Chiofalo G, Picciotto M, Carboni R, et al. Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? Anticancer Res 2003; 23:1923-1926.
44. Raff JP, Rajdev L, Malik U, Novik Y, Manalo JM, Negassa A, et al. Phase II study of weekly docetaxel alone or in combination with traszumab in patients with metastatic breast cancer. Clin Breast Cancer 2004; 4:420-427.
45. Hainsworth JD, Burris HA 3rd, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19:3500-3505.
46. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334:677-681.
47. Grosset AB, Spiro TE, Beynon J, Rodgers GM. Enoxaparin, a low-molecular-weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism. Thromb Res 1997; 86:349-354.
48. Fishman A, Altaras M, Klein Z, Aviram R, Beyth Y. Low molecular heparin (enoxaparin) as an alternative treatment of acute deep venous thrombosis in gynecologic oncology patients. Eur J Gynaecol Oncol 1996; 17:365-367.
49. Hirtenlehner K, Pec M, Kubista E, Singer CF. Influences of stroma-derived growth factors on the cytokine expression pattern of human breast cancer cell lines. Arch Gynecol Obstet 2002; 266:108-113.
50. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, et al. Plasma fibrin D-dimer levels correlate with tumor volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86:389-395.
51. Dempfle CE, Zips S, Ergul H, Heene DL, FACT study group. The fibrin assay comparison trial (FACT): correlation of soluble fibrin assays with D-dimer. Thromb Haemost 2001; 86:1204-1209.
52. Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer T, et al. Coagulation markers predict survival in cancer patients. Thromb Haemost 2002; 88:745-749.